In response to the growing cancer threats, OncoDxRx is ramping up its drug response prediction (DRP) capabilities. OncoDxRx has launched PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) test, and plans are underway to increase its adoption significantly. The strategic focus is on expanding PGA market and integrating into current precision oncology testing workup, reinforcing the lessons learned from personalized and precision medicine.

The war against cancer has underscored the importance of DRP capability in contemporary targeted therapy. The industry has deployed a wide range of biomarker testing (or companion diagnostics) for treatment decision-making, transforming clinical doctrines. Unfortunately, NGS biomarker testing only qualify 20-30% of cancer patients, if taking into account of response rate, only about 10-20% patients actually benefit from precision medicine.

OncoDxRx’s PGA provides unprecedented real-time real-life drug-mapping capability, enabling faster decision-making and more precise drug efficacy prediction. For clinical labs like those using NGS comprehensive genomic profiling, PGA gap-fills the unmet need for patient “NON-RESPONDERS”, complements biomarker testing, while completing test menu and benefiting many more cancer patients.

As a result, precision diagnostic companies worldwide should be adopting similar tactics, integrating PGA into their operations to maintain competitive superiority. OncoDxRx’s use of PGA technology in coordination with the NGS biomarker testing exemplifies how cancer-fighting lessons are being applied to enhance therapeutic effectiveness in the face of evolving cancer threats.

This new PGA approach, shaped by lessons learned from the ongoing cancer war, reflects the increasing reliance on DRP in modern therapy guidance. Personalized medicine has demonstrated the vital role of DRP in enhancing actionability and targeting precision, while also minimizing human exposure to high-risk drug toxicity.

“OncoDxRx has taken note of the challenges of tumor evolution and is increasing its focus on this area.” In the past few years “we’ve refined our knowledge and master our technologies to counter it,” said OncoDxRx.

In conclusion, OncoDxRx’s focus on PGA-powered DRP tactics marks a significant shift in treatment selection strategy for those patients unresponsive to precision medicine. By leveraging the experience of PGA development and continuously improving its technological capabilities, OncoDxRx is positioning itself at the forefront of modern theranostics.